Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The collaboration pairs Chai Discovery’s molecule-search AI with Eli Lilly’s TuneLab platform approach, aiming to speed early-stage discovery for a limited group of biotech partners.
THE APEX TIMES
THE APEX TIMES
On CNBC’s Mad Money, Jim Cramer singled out Eli Lilly as a stock he wanted viewers to hold, framing the company as a name worth staying with even as he also discussed other market topics.
THE APEX TIMES
As public discussion around manufacturing-specific messaging quiets, investors and analysts are reading the shift as evidence of a larger change in how Eli Lilly is executing its multi-year growth plan.
THE APEX TIMES
The U.S. pharma company said it will reduce a previously announced €2.7 billion investment in Germany, tying the decision to upcoming or ongoing European drug pricing reforms that it says could reshape the economics of future research and manufacturing.
THE APEX TIMES
A reported new GLP-2 deal with Hanmi Pharm underscores how Lilly is trying to expand its GLP platform beyond weight loss into broader gastrointestinal disease.
THE APEX TIMES
The deal adds another non-opioid pain therapy effort to Eli Lilly’s growing portfolio, continuing a recent streak of acquisitions that have totaled more than $18 billion over the past few years.
THE APEX TIMES
Eli Lilly (LLY) said it acquired Austin-based 4E Therapeutics to accelerate development of next-generation treatments aimed at chronic pain, part of an industry-wide shift away from opioid-based care.
THE APEX TIMES
Lilly’s planned purchase of 4E Therapeutics would broaden its neuroscience and anti-cancer research footprint, pairing the expansion with an incremental clinical update for Jaypirca, its targeted treatment for certain leukemias.
THE APEX TIMES
A fresh piece of market commentary frames Eli Lilly versus Novo Nordisk as a contest for leadership in obesity medications, highlighting the two companies’ long competitive history while providing few concrete updates.
